3.0
12 June 2026
Former employee, more than 1 year
Salt Lake City, UT
Recommend
CEO approval
Business outlook
Pros
Diversity of medical device projects; High volume chemistry workstream from three laboratories; Business model maximizes consulting revenues with optimized pricing
Cons
Similar to other publicly traded companies, tends to be a bit hyper-focused on month-to-month and quarterly revenues.